Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study
Chloe I. Bloom aff001; Laure de Preux aff002; Aziz Sheikh aff003; Jennifer K. Quint aff001
Působiště autorů: National Heart and Lung Institute, Imperial College London, London, United Kingdom aff001; Imperial College Business School, Imperial College London, London, United Kingdom aff002; Asthma UK Centre for Applied Research, Usher Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom aff003
Vyšlo v časopise: Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study. PLoS Med 17(7): e32767. doi:10.1371/journal.pmed.1003145
Kategorie: Research Article
Guidelines recommend stepping down asthma treatment to the minimum effective dose to achieve symptom control, prevent adverse side effects, and reduce costs. Limited data exist on asthma prescription patterns in a real-world setting. We aimed to evaluate the appropriateness of doses prescribed to a UK general asthma population and assess whether stepping down medication increased exacerbations or reliever use, as well as its impact on costs.
Methods and findings
We used nationwide UK primary care medical records, 2001–2017, to identify 508,459 adult asthma patients managed with preventer medication. Prescriptions of higher-level medication: medium/high-dose inhaled corticosteroids (ICSs) or ICSs + add-on medication (long-acting β2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline, or long-acting muscarinic antagonist [LAMA]) steadily increased over time (2001 = 49.8%, 2017 = 68.3%). Of those prescribed their first preventer, one-third were prescribed a higher-level medication, of whom half had no reliever prescription or exacerbation in the year prior. Of patients first prescribed ICSs + 1 add-on, 70.4% remained on the same medication during a mean follow-up of 6.6 years. Of those prescribed medium/high-dose ICSs as their first preventer, 13.0% already had documented diabetes, cataracts, glaucoma, or osteopenia/osteoporosis. A cohort of 125,341 patients were drawn to assess the impact of stepping down medication: mean age 50.4 years, 39.4% males, 39,881 stepped down. Exposed patients were stepped down by dropping their LABAs or another add-on or by halving their ICS dose (halving their mean-daily dose or their inhaler dose). The primary and secondary outcomes were, respectively, exacerbations and an increase in reliever prescriptions. Multivariable regression was used to assess outcomes and determine the prognostic factors for initiating stepdown. There was no increased exacerbation risk for each possible medication stepdown (adjusted hazard ratio, 95% CI, p-value: ICS inhaler dose = 0.86, 0.77–0.93, p < 0.001; ICS mean daily = 0.80, 0.74–0.87, p < 0.001; LABA = 1.01, 0.92–1.11, p = 0.87, other add-on = 1.00, 0.91–1.09, p = 0.79) and no increase in reliever prescriptions (adjusted odds ratio, 95% CI, p-value: ICS inhaler dose = 0.99, 0.98–1.00, p = 0.59; ICS mean daily = 0.78, 0.76–0.79, p < 0.001; LABA = 0.83, 0.82–0.85, p < 0.001; other add-on = 0.86, 0.85–0.87, p < 0.001). Prognostic factors to initiate stepdown included medication burden, but not medication side effects. National Health Service (NHS) indicative prices were used for cost estimates. Stepping down medication, either LABAs or ICSs, could save annually around £17,000,000 or £8,600,000, respectively. Study limitations include the possibility that prescribed medication may not have been dispensed or adhered to and the reason for stepdown was not documented.
In this UK study, we observed that asthma patients were increasingly prescribed higher levels of treatment, often without clear clinical indication for such high doses. Stepping down medication did not adversely affect outcomes and was associated with substantial cost savings.
Adverse reactions – Asthma – Cataracts – diabetes mellitus – Drug therapy – Primary care – Receptor antagonist therapy – Treatment guidelines
1. Suissa S, Ernst P. Inhaled corticosteroids: Impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001 Jun;107(6):937–44. doi: 10.1067/mai.2001.115653 11398069
2. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep 1;5(9):691–706. doi: 10.1016/S2213-2600(17)30293-X 28822787
3. British Thoracic Society. BTS/SIGN British guideline on the management of asthma [Internet]. 2019 [cited 2019 Oct 1]. Available from: https://brit-thoracic.org.uk/quality-improvement/guidelines/asthma/
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]. 2017 [cited 2019 Oct 1]. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf
5. NHLBI. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
6. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018 Mar;15(3):348–56. doi: 10.1513/AnnalsATS.201703-259OC 29323930
7. Bedouch P, Marra CA, FitzGerald JM, Lynd LD, Sadatsafavi M. Trends in Asthma-Related Direct Medical Costs from 2002 to 2007 in British Columbia, Canada: A Population Based-Cohort Study. PLoS ONE. 2012 Dec 5;7(12):e50949. doi: 10.1371/journal.pone.0050949 23227222
8. Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä R-L, et al. The Finnish experience to save asthma costs by improving care in 1987–2013. J Allergy Clin Immunol. 2017 Feb;139(2):408–414.e2. doi: 10.1016/j.jaci.2016.12.001 27979429
9. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J. 2004 Apr 1;23(4):552–8. doi: 10.1183/09031936.04.00076604 15083753
10. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004 Jan;59(1):16–20. 14694240
11. Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. Am J Respir Crit Care Med. 2019 Jun 15;199(12):1471–7. doi: 10.1164/rccm.201810-1868CI 30645143
12. Covvey JR, Johnston BF, Wood F, Boyter AC. Changes to inhaled corticosteroid dose when initiating combination inhaler therapy in long-acting β agonist-naïve patients with asthma: a retrospective database analysis. Thorax. 2014 Nov;69(11):1056–8. doi: 10.1136/thoraxjnl-2013-204944 24430175
13. Australian Centre for Asthma Monitoring. Asthma in Australia. Canberra, Australia: Australian Institute for Health and Welfare; 2005.
14. Yawn BP, Wollan PC, Bertram SL, Lowe D, Butterfield JH, Bonde D, et al. Asthma Treatment in a Population-Based Cohort: Putting Step-Up and Step-Down Treatment Changes in Context. Mayo Clin Proc. 2007 Apr 1;82(4):414–21. doi: 10.4065/82.4.414 17418068
15. Bloom CI, Palmer T, Feary J, Quint JK, Cullinan P. Exacerbation Patterns in Adults with Asthma in England. A Population-based Study. Am J Respir Crit Care Med. 2019 Feb 15;199(4):446–53. doi: 10.1164/rccm.201808-1516OC 30507307
16. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Staa T van, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36. doi: 10.1093/ije/dyv098 26050254
17. Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 2017 Aug 11;7(8):e017474. doi: 10.1136/bmjopen-2017-017474 28801439
18. Quint JK, Mullerova H, DiSantostefano RL, Forbes H, Eaton S, Hurst JR, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014 Jul 23;4(7):e005540–e005540. doi: 10.1136/bmjopen-2014-005540 25056980
19. Crossingham I, Evans DJ, Halcovitch NR, Marsden PA. Stepping down the dose of inhaled corticosteroids for adults with asthma. Cochrane Database Syst Rev. 2017 Feb 1;2:CD011802. doi: 10.1002/14651858.CD011802.pub2 28146601
20. Bloom CI, Nissen F, Douglas IJ, Smeeth L, Cullinan P, Quint JK. Exacerbation risk and characterisation of the UK’s asthma population from infants to old age. Thorax. 2018 Apr 1;73(4):313–20. doi: 10.1136/thoraxjnl-2017-210650 29074814
21. Silver HS, Blanchette CM, Kamble S, Petersen H, Letter MA, Meddis D, et al. Relationship between short-acting β2-adrenergic agonist use and healthcare costs. Am J Manag Care. 2011 Jan;17(1):19–27. 21348565
22. Schatz M, Zeiger RS, Vollmer WM, Mosen D, Apter AJ, Stibolt TB, et al. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol. 2006 May;117(5):995–1000. doi: 10.1016/j.jaci.2006.01.053 16675324
23. Patel M, Pilcher J, Reddel HK, Pritchard A, Corin A, Helm C, et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy. 2013 Jun;43(10):1144–1151. doi: 10.1111/cea.12166 24074332
24. Slejko JF, Ghushchyan VH, Sucher B, Globe DR, Lin S-L, Globe G, et al. Asthma control in the United States, 2008–2010: Indicators of poor asthma control. J Allergy Clin Immunol. 2014 Jun;133(6):1579–87. doi: 10.1016/j.jaci.2013.10.028 24331376
25. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika. 1994 Aug;81(3):515.
26. Business Services Authority NHS. Dictionary of medicines and devices (dm+d) | NHSBSA [Internet]. 2019 [cited 2019 Oct 1]. Available from: https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd
27. Bloom C, Saglani S, Feary J, Jarvis D, Quint J. Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population based cohort 2006 to 2016. Eur Respir J. 2019;53(4): 1802130. doi: 10.1183/13993003.02130-2018 30765507
28. Thomas M, Leather D, Price D. High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. Prim Care Respir J. 2006 Jun;15(3):166–72. doi: 10.1016/j.pcrj.2006.02.009 16757397
29. Thomas M, Murray-Thomas T, Fan T, Williams T, Taylor S. Prescribing patterns of asthma controller therapy for children in UK primary care: A cross-sectional observational study. BMC Pulm Med. 2010 May 14;10: 29. doi: 10.1186/1471-2466-10-29 20470409
30. Fowler SJ, O’Byrne PM, Buhl R, Shaw D. Two pathways, one patient; UK asthma guidelines. Thorax. 2018 Sep;73(9):797–8. doi: 10.1136/thoraxjnl-2018-211703 29724867
31. Lugtenberg M, Burgers JS, Han D, Westert GP. General practitioners’ preferences for interventions to improve guideline adherence. J Eval Clin Pract. 2014 Dec 1;20(6):820–6. doi: 10.1111/jep.12209 24953439
32. Austad B, Hetlevik I, Mjølstad BP, Helvik A-S. Applying clinical guidelines in general practice: a qualitative study of potential complications. BMC Fam Pract. 2016;17:92. doi: 10.1186/s12875-016-0490-3 27449959
33. Breton MC, LeLorier J, Forget A, Blais L. Use of combination therapy in asthma: Are they prescribed according to guidelines. Respir Med. 2007 Sep;101(9):1916–23. doi: 10.1016/j.rmed.2007.04.017 17629690
34. Yawn BP, Rank MA, Cabana MD, Wollan PC, Juhn YJ. Adherence to Asthma Guidelines in Children, Tweens, and Adults in Primary Care Settings: A Practice-Based Network Assessment. Mayo Clin Proc. 2016 Apr;91(4):411–21. doi: 10.1016/j.mayocp.2016.01.010 26944837
35. Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1877–87. doi: 10.1056/NEJMoa1715275 29768147
36. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1865–76. doi: 10.1056/NEJMoa1715274 29768149
37. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. N Engl J Med. 2019 May 23;380(21):2020–30. doi: 10.1056/NEJMoa1901963 31112386
38. Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019 Sep 14;394(10202):919–28. doi: 10.1016/S0140-6736(19)31948-8 31451207
39. Bloom CI, Douglas I, Olney J, D’ancona G, Smeeth L, Quint JK. Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax. 2019 Nov 1;74(11):1076–84.
40. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, et al. Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. JAMA. 2017 Jan 17;317(3):269–79. doi: 10.1001/jama.2016.19627 28114551
41. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta 2 -agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 Jun;(6):CD011306. doi: 10.1002/14651858.CD011306.pub2 26089258
42. Jabbal S, Manoharan A, Anderson W, Lipworth J, Lipworth B. Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma. Ann Allergy, Asthma Immunol. 2016 Oct;117(4):430–1.
43. Rank MA, Liesinger JT, Branda ME, Gionfriddo MR, Schatz M, Zeiger RS, et al. Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. J Allergy Clin Immunol. 2016 May;137(5):1373–1379.e3. doi: 10.1016/j.jaci.2015.08.035 26506020
44. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults. JAMA. 2018 Nov 13;320(18):1889. doi: 10.1001/jama.2018.16131 30422193
45. Reeve E, Wolff JL, Skehan M, Bayliss EA, Hilmer SN, Boyd CM. Assessment of Attitudes Toward Deprescribing in Older Medicare Beneficiaries in the United States. JAMA Intern Med. 2018 Dec;178(12):1673. doi: 10.1001/jamainternmed.2018.4720 30326004
46. Avery AJ, Bell BG. Rationalising medications through deprescribing. BMJ. 2019 Feb 7;364:l570. doi: 10.1136/bmj.l570 30733211
47. Siddaway D. Stepping down asthma treatment: perceptions of primary care staff. Nurs Times. 2018;114: 4, 18.
48. Health and Social Care Information Centre. Prescription Cost Analysis—England, 2012 [Internet]. 2013 [cited 2019 Oct 1]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2012.
49. Health and Social Care Information Centre. Prescriptions dispensed in the community: England 2002–2012 [Internet]. 2013 [cited 2019 Oct 1]. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescriptions-dispensed-in-the-community/prescriptions-dispensed-in-the-community-statistics-for-england-2002-2012.
50. Inhaler Error Steering Committee D, Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013 Jan;107(1):37–46. doi: 10.1016/j.rmed.2012.09.017 23098685
51. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002 Feb;19(2):246–51. doi: 10.1183/09031936.02.00218402 11866004
52. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017 Mar 13;3:CD012286. doi: 10.1002/14651858.CD012286.pub2 28288272
53. Bloom CI, Walker S, Quint JK. Inadequate specialist care referrals for high-risk asthma patients in the UK: an adult population-based cohort 2006–2017. J Asthma. 2019: 1–7.
Článek vyšel v časopise
2020 Číslo 7
- Co se skrývá za ChatGPT? Umělá inteligence s potenciálním využitím i v klinické medicíně
- Macmiror complex − možnosti a úskalí terapie
- Perorální semaglutid ve formě tablet k léčbě DM 2. typu nyní dostupný i v Česku
- Odvrácená tvář Z-hypnotik
- Ibuprofen jako alternativa antibiotik při léčbě infekcí močových cest
Nejčtenější v tomto čísle
- Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank
- Participation in adherence clubs and on-time drug pickup among HIV-infected adults in Zambia: A matched-pair cluster randomized trial
- Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe
- Neonatal outcome in 29 pregnant women with COVID-19: A retrospective study in Wuhan, China
Zvyšte si kvalifikaci online z pohodlí domova
Deprese u dětí a adolescentůnový kurz